Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.
You may also be interested in...
Exelon Approved For Parkinson’s Dementia
FDA approved Novartis' Exelon (rivastigmine) June 27 for treatment of mild to moderate dementia related to Parkinson's disease
Exelon Approved For Parkinson’s Dementia
FDA approved Novartis' Exelon (rivastigmine) June 27 for treatment of mild to moderate dementia related to Parkinson's disease
Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition
Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.